Sensorion Provides Preliminary Documents for the Combined Shareholders' General Meeting of May 24, 2023

Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company's shareholders

Related Keywords

Paris ,France General ,France ,French ,David Lawrence ,Square Louvois ,Institut Pasteur ,Communications Europe France ,Consilium Strategic Communications ,International Media Relations ,Regulatory News ,Combined General Meeting ,French Commercial Code ,General Meeting ,Annual General Meeting ,Combined Shareholder General Meeting ,Cisplatin Induced Ototoxicity ,Cochlear Limited ,Sudden Sensorineural Hearing Loss ,Chief Financial Officer ,United Kingdom ,Investor Relations ,Strategic Communications ,Sue Stuart ,Sensorion ,Rovides ,Reliminary ,Documents ,Combined ,Shareholders ,Eneral ,Meeting ,023 ,